Skip to content
BioLab
Back to Labs
Literature Workspace
Research article 2020 Reviewed

Nivolumab in children and young adults with relapsed or refractory solid tumours or lymphoma (ADVL1412): a multicentre, open-label, single-arm, phase 1–2 trial

Kara L Davis, Elizabeth Fox, Melinda S Merchant, Joel M Reid, Rachel A Kudgus, Xiaowei Liu, Charles G Minard, Stephan Voss, Stacey L Berg, Brenda J Weigel, Crystal L Mackall

The Lancet OncologyElsevier BV

Evidence snapshot note

This reference is cited by the validated MVA · BUB1B evidence snapshot (data as of 2026-10-17) as Nivolumab in children and young adults with relapsed or refractory solid tumours or lymphoma (ADVL1412).

Model in the source
Pediatric and young-adult relapsed/refractory malignancies; phase 1-2.
Where in the publication
Abstract, findings and interpretation; no figure-level extraction.
Cited by evidence records
MVA-IMMUNE-011

The note describes how the snapshot used the source; it is not a summary of the publication's conclusions.

Identifiers and provenance

DOI
10.1016/s1470-2045(20)30023-1
PMID
32192573
PMCID
PMC7255545
Metadata from
Crossref, Europe PMC, OpenAlex, fetched
License (as declared by the source)
https://www.elsevier.com/tdm/userlicense/1.0/
Open access
Not flagged
Added
from the MVA evidence snapshot

In the library

Tags
None yet
Keywords from the source
PD-1 inhibitors, childhood cancer, lymphoma, rhabdomyosarcoma, Ewing sarcoma, osteosarcoma, neuroblastoma, Hodgkin's disease, non-Hodgkin lymphoma, melanoma, immune checkpoint inhibitors, safety and tolerability

KBot · Research guide

Prewritten answers · Evidence linked

KBot

Hello, I am KBot, the BioLab research guide. I can explain the research cases, the Literature Workspace, the Evidence Graph and the analysis tools, and where each one stops. Choose a topic below. These are prewritten explanations, not a live AI consultation.

Research information, not individual medical advice. No messages are sent or saved.